党永军：重庆医科大学特聘教授
党永军，重庆医科大学特聘教授，生命科学研究院新靶标与化学干预研究中心主任，博士生导师。复旦大学遗传所博士，美国约翰霍普金斯大学医学院博士后，中国药理学会海洋药物药理专业委员会副主任委员，全国卫生产业企业管理协会医学遗传专委会常务委员，上海药理学会常务理事。
主要从事与疾病相关新靶标和小分子化合物的发现与确证及转化医学研究，建立了与疾病相关的分子靶标鉴定和小分子筛选的系统体系。近五年在重大疾病新靶标发现领域，在Nature、Nat Commun、Cell Res、Diabetes等知名期刊发表学术论文20余篇，通讯作者身份发表论文10余篇，其中影响因子大于10分的论文7篇，文章总影响因子超过300，总引用次数超过3,600次，H因子28。主持国家自然科学基金面上项目3项，参与国家重点研发计划“深海关键技术与装备”重点专项子课题1项，参与国家重点研发计划1项。申请国内专利16项，国际专利2项，实现项目转化总金额3.28亿人民币。担任Blood、Cell Chem Biol、 Bioorg Med Chem Lett、Exp Cell Res、ACS Synth Biol等知名杂志审稿人。
主要研究方向：1）天然产物和药物的分子靶点鉴定和作用机制研究；2）基于小分子探针的基础生物学理论研究；3）建立适于高通量筛选的细胞和动物模型用于新药的筛选和研发。
联系邮箱：yjdang /at cqmu.edu.cn
代表论文：
1. X Li#, Y Zhang#, Y Fu#, H Zhang, H Li, Q Li, H Li, R Tan, C Jiang, W Jiang, Z Li, C Luo*, B Lu*,Y Dang* (2021). Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex. Acta Pharmacol Sin. Online ahead of print.
2. Z Wang#, Z Li#, W Zhao, H Huang, J Wang, H Zhang, J Lu, R Wang, W Li, Z Cheng, W Xu, D Zhu, L Zhou, W Jiang, L Yu, J Liu, C Luo, H Zhu, D Ye, W Pan, J Ju, Y Dang* (2020). Identification and characterization of isocitrate dehydrogenase 1 (IDH1) as a functional target of marine natural product grincamycin B. Acta Pharmacol Sin. Online ahead of print.
3. R Tan, W Du, Y Liu, X Cong, M Bai, C Jiang, Z Li, M Tan, DK Ma, Q. Huang*, W Jiang*, Y Dang* (2020). Nucleolus localization of SpyCas9 affects its stability and interferes with host protein translation in mammalian cells. Genes & Diseases. In press.
4. Z Cui#, Y Liu#, W Wan#, Y Xu, Y Hu, M Ding, X Dou, R Wang, H Li, Y Meng, W Li, W Jiang, Z Li, Y Li, M Tan, DK Ma, Y Ding, JO Liu, C Luo*, B Yu*, Q Tang*, Y Dang* (2020). Ethacrynic acid targets GSTM1 to ameliorate obesity by promoting browning of white adipocytes. Protein Cell. 2020, Online ahead of print.
5. Z Sun#, H Zhang#, Y Zhang#, L Liao#, W Zhou#, F Zhang, F Lian, J Huang, P Xu, R Zhang, W Lu, M Zhu, H Tao, F Yang, H Ding, S Chen, L Yue, B Zhou, N Zhang, M Tan, H Jiang, K Chen, B Liu*, C Liu*, Y Dang*, C Luo* (2020). Covalent inhibitors allosterically block the activation of Rho family proteins and suppress cancer cell invasion. Adv Sci. 7(14): 2000098.
6. C Jiang#, Y Tang#, L Ding, R Tan, X Li, J Lu, J Jiang, Z Cui, Z Tang, W Li, Z Cao, T Schneider-Poetsch, W Jiang, C Luo, Y Ding*, J Liu*, Y Dang* (2019). Targeting the N Terminus of eIF4AI for Inhibition of Its Catalytic Recycling. Cell Chem Biol. 26(10): 1417-1426 e1415.
7. S Jiang #, J Wang#, C Yang#, R Tan#, J Hou, Y Shi, H Zhang, S Ma, J Wang, M Zhang, G Philips, Z Li, J Ma, W Yu, G Wang, Y Wu, R Schlegel, H Wang, S Cao, J Guo*, X Liu*, Y Dang* (2019). Continuous culture of urine-derived bladder cancer cells for precision medicine. Protein Cell. 10(12): 902-907.
8. W Jiang#, X Zhou#, Z Li#, K Liu, W Wang, R Tan, X Cong, J Shan, Y Zhan, Z Cui, L Jiang, Q Li, S Shen, M Bai, Y Cheng, B Li, M Tan, D Ma, J.O Liu, Y Dang* (2018). Prolyl 4-Hydroxylase 2 Promotes B-cell Lymphoma Progression via Hydroxylation of Carabin. Blood. 131(12): 1325-1336.
9. Z Li#, Z Cheng#, C Raghothama, Z Cui, K Liu, X Li, C Jiang, W Jiang, M Tan, X Ni, A Pandey, J.O Liu, Y Dang* (2018). USP9X controls translation efficiency via deubiquitination of eukaryotic translation initiation factor 4A1. Nucleic Acids Res. 46(2): 823–839.
10. Y Yao #, S Sun#, F Fei, J Wang, Y Wang, R Zhang, J Wu, L Liu, X Liu, Z Cui, Q Li, M Yu, Y Dang*, X Wang* (2017). Screening in larval zebrafish reveals tissue-specific distribution offifteen fluorescent compounds. Dis Model Mech. 10: 1155-1164.
11. P Lu, F Zhang, S Qian, X Li, Z Cui, Y Dang*, QQ Tang*. (2016) Artemisinin derivatives prevent obesity by inducing browning of WAT and enhancing BAT function. Cell Res. 26(10):1169-1172.
12. J Lu#, C Jiang#, X Li#, L Jiang, Z Li, T Schneider-Poetsch, J Liu, K Yu, J.O Liu, H Jiang, C Luo*,Y Dang* (2015). A gating mechanism for Pi release governs the mRNA unwinding by eIF4AI during translation initiation. Nucleic Acids Res. 43(21):10157-67.
13. W Jiang, H Huang, L Ding, P Zhu, H Saiyin, G Ji, J Zuo, D Han, Y Pan, D Ding, X Ma, Y Zhang, J Wu, Q Yi, J.O Liu, H Huang, Y Dang*, L Yu* (2015). Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 20(34):4460-70.
14. Y Dang#, T Schneider-Poetsch#, DE Eyler, JC Jewett, S Bhat, VH Rawal, R Green, J.O Liu (2011). Inhibition of Eukaryotic Translation Elongation by the Antitumor Natural Product Mycalamide B. RNA. 17(8): 1578-1588.
15. Y Dang, W.K Low, J Xu, N.H Gehring, H.C Dietz, D Romo, J.O Liu (2009). Inhibition of nonsense-mediated mRNA decay by the natural product pateamine A through eukaryotic initiation factor 4AIII. J Biol Chem. 284: 23613-23621.
16. Y Dang, N Kedersha, W.K Low, D Romo, M Gorospe, R Kaufman, P Anderson, J.O Liu (2006). Eukaryotic initiation factor 2alpha-independent pathway of stress granule induction by the natural product pateamine A. J Biol Chem. 281: 32870-32878.
17. W.K Low#, Y Dang#, T Schneider-Poetsch, Z Shi, N.S Choi, W.C Merrick, D Romo, J.O Liu (2005). Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell. 20: 709-722.
(Featured in the review by Dr. Jon Clardy in ACS Chemical Biology “Stopping Trouble before It starts” 2005 Vol. 1 No. 1 p17; Highlighted in C & EN News “Protein Synthesis Nipped in the Bud” on December 19, 2005; Commented in “Faculty of 1000”)
18. H He#, Y Dang#, F Dai, Z Guo, J Wu, X She, Y Pei, Y Chen, W Ling, C Wu (2003). Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. J Biol Chem. 278: 29278-29287.
19. Z Li#, C Wang#, Z Wang#, C Zhu#, J Li, T Sha, L Ma, C Gao, Y Yang, Y Sun, J Wang, X Sun, C Lu, M Difiglia, Y Mei, C Ding, S Luo, Y Dang, Y Dang*, Y Fei* and B Lu* (2019). Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature. 575(7781): 203-209.
党氏家族报——汇天下党氏，报家族文化！